Literature DB >> 25988889

Antibody responses to envelope glycoproteins in HIV-1 infection.

Dennis R Burton1, John R Mascola2.   

Abstract

Antibody responses to the HIV-1 envelope glycoproteins can be classified into three groups. Binding but non-neutralizing responses are directed to epitopes that are expressed on isolated envelope glycoproteins but not on the native envelope trimer found on the surface of virions and responsible for mediating the entry of virus into target cells. Strain-specific responses and broadly neutralizing responses, in contrast, target epitopes that are expressed on the native trimer, as revealed by recently resolved structures. The past few years have seen the isolation of many broadly neutralizing antibodies of remarkable potency that have shown prophylactic and therapeutic activities in animal models. These antibodies are helping to guide rational vaccine design and therapeutic strategies for HIV-1.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25988889      PMCID: PMC4834917          DOI: 10.1038/ni.3158

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  107 in total

Review 1.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

2.  Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.

Authors:  Pascal Poignard; Maxime Moulard; Edwin Golez; Veronique Vivona; Michael Franti; Sara Venturini; Meng Wang; Paul W H I Parren; Dennis R Burton
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors:  P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus.

Authors:  D C Montefiori; I Y Zhou; B Barnes; D Lake; E M Hersh; Y Masuho; L B Lefkowitz
Journal:  Virology       Date:  1991-06       Impact factor: 3.616

5.  Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies.

Authors:  Yoshiaki Nishimura; Tatsuhiko Igarashi; Nancy Haigwood; Reza Sadjadpour; Ron J Plishka; Alicia Buckler-White; Riri Shibata; Malcolm A Martin
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

8.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 9.  Defining the protective antibody response for HIV-1.

Authors:  John R Mascola
Journal:  Curr Mol Med       Date:  2003-05       Impact factor: 2.222

10.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

View more
  224 in total

1.  New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.

Authors:  Nicole A Doria-Rose; Jinal N Bhiman; Ryan S Roark; Chaim A Schramm; Jason Gorman; Gwo-Yu Chuang; Marie Pancera; Evan M Cale; Michael J Ernandes; Mark K Louder; Mangaiarkarasi Asokan; Robert T Bailer; Aliaksandr Druz; Isabella R Fraschilla; Nigel J Garrett; Marissa Jarosinski; Rebecca M Lynch; Krisha McKee; Sijy O'Dell; Amarendra Pegu; Stephen D Schmidt; Ryan P Staupe; Matthew S Sutton; Keyun Wang; Constantinos Kurt Wibmer; Barton F Haynes; Salim Abdool-Karim; Lawrence Shapiro; Peter D Kwong; Penny L Moore; Lynn Morris; John R Mascola
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

Review 2.  A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds.

Authors:  Thomas J Hope; Jeanne M Marrazzo
Journal:  AIDS Res Hum Retroviruses       Date:  2015-11       Impact factor: 2.205

3.  Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Authors:  Shilpa Patil; Rajesh Kumar; Suprit Deshpande; Sweety Samal; Tripti Shrivastava; Saikat Boliar; Manish Bansal; Nakul Kumar Chaudhary; Aylur K Srikrishnan; Kailapuri G Murugavel; Suniti Solomon; Melissa Simek; Wayne C Koff; Rajat Goyal; Bimal K Chakrabarti; Jayanta Bhattacharya
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

4.  Using homology modeling to interrogate binding affinity in neutralization of ricin toxin by a family of single domain antibodies.

Authors:  Andrea Bazzoli; David J Vance; Michael J Rudolph; Yinghui Rong; Siva Krishna Angalakurthi; Ronald T Toth; C Russell Middaugh; David B Volkin; David D Weis; John Karanicolas; Nicholas J Mantis
Journal:  Proteins       Date:  2017-08-04

Review 5.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

6.  Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.

Authors:  Paola Martinez-Murillo; Karen Tran; Javier Guenaga; Gustaf Lindgren; Monika Àdori; Yu Feng; Ganesh E Phad; Néstor Vázquez Bernat; Shridhar Bale; Jidnyasa Ingale; Viktoriya Dubrovskaya; Sijy O'Dell; Lotta Pramanik; Mats Spångberg; Martin Corcoran; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

Review 7.  Variation, Indispensability, and Masking in the M protein.

Authors:  Partho Ghosh
Journal:  Trends Microbiol       Date:  2017-08-31       Impact factor: 17.079

8.  Determinants of HIV-1 broadly neutralizing antibody induction.

Authors:  Peter Rusert; Roger D Kouyos; Claus Kadelka; Hanna Ebner; Merle Schanz; Michael Huber; Dominique L Braun; Nathanael Hozé; Alexandra Scherrer; Carsten Magnus; Jacqueline Weber; Therese Uhr; Valentina Cippa; Christian W Thorball; Herbert Kuster; Matthias Cavassini; Enos Bernasconi; Matthias Hoffmann; Alexandra Calmy; Manuel Battegay; Andri Rauch; Sabine Yerly; Vincent Aubert; Thomas Klimkait; Jürg Böni; Jacques Fellay; Roland R Regoes; Huldrych F Günthard; Alexandra Trkola
Journal:  Nat Med       Date:  2016-09-26       Impact factor: 53.440

9.  Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Authors:  Daniel T Claiborne; Timothy E Dudek; Colby R Maldini; Karen A Power; Musie Ghebremichael; Edward Seung; Elizabeth F Mellors; Vladimir D Vrbanac; Katharine Krupp; Abigail Bisesi; Andrew M Tager; David M Knipe; Christian L Boutwell; Todd M Allen
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

10.  Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection.

Authors:  Yanling Wu; Jing Xue; Chunyu Wang; Wei Li; Lili Wang; Weizao Chen; Ponraj Prabakaran; Desheng Kong; Yujia Jin; Dan Hu; Yulu Wang; Cheng Lei; Diao Yu; Chao Tu; Ariola Bardhi; Igor Sidorov; Liying Ma; Harris Goldstein; Chuan Qin; Lu Lu; Shibo Jiang; Dimiter S Dimitrov; Tianlei Ying
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.